AtG Therapeutics is a pioneering biotech startup focused on developing innovative drugs and biomarkers to combat cancer therapeutic resistance. Based in Barcelona, Spain, AtG operates in the oncology sector, specifically targeting the challenge of cancer cells becoming resistant to existing treatments. This resistance often leads to treatment failure and poor patient outcomes, making AtG's mission critical in the fight against cancer.

AtG serves a diverse range of clients, including pharmaceutical companies, healthcare providers, and research institutions. These clients are interested in cutting-edge solutions to improve cancer treatment efficacy and patient selection for therapies. By offering novel drug candidates and biomarkers, AtG aims to enhance the precision and effectiveness of cancer treatments.

The company's business model revolves around research and development (R&D) of new therapeutic agents and diagnostic tools. AtG generates revenue through partnerships, licensing agreements, and grants. For instance, the company has been recognized and awarded by organizations such as FIPSE and has participated in programs like CRAASH, which support innovative healthcare startups.

AtG's primary products include new small molecule drug candidates and biomarkers that help in patient selection technology. These products are designed to identify which patients are most likely to benefit from specific cancer treatments, thereby increasing the success rates of these therapies. The company is advancing its portfolio of therapies to clinical trials, aiming to bring these groundbreaking solutions to market and improve the lives of cancer patients.

In summary, AtG Therapeutics is at the forefront of addressing cancer therapeutic resistance through its innovative drug and biomarker development. The company operates in the oncology market, serving pharmaceutical companies, healthcare providers, and research institutions, and generates revenue through R&D, partnerships, and licensing.

Keywords: oncology, cancer resistance, biomarkers, drug development, patient selection, small molecule, therapeutic target, clinical trials, biotech startup, precision medicine.